- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02302651
Non-invasive Focal Therapy for Osteoid Osteoma
Treatment of Osteoid Osteoma With MR Guided High Intensity Focused Ultrasound
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An osteoid osteoma is a benign, painful musculoskeletal tumor that usually occurs in young males. The standard of care in the United States is computed tomography (CT)-guided radiofrequency ablation, a minimally invasive percutaneous procedure, with clinical success rates ranging between 85% and 98%.
Percutaneous or surgical therapy can lead to non-negligible side-effects and limited efficacy for pediatric population or young adults with osteoid osteoma. We investigate whether selective focal ablation of osteoid lesions can reduce this treatment burden without compromising long-term clinical efficacy.
Treatments will be performed using a 3.0-T MR unit (Discovery MR 750; GE Medical Systems, Milwaukee,Wis) featuring a Conformité Européenne-approved ExAblate MR-guided focused ultrasound system (InSightec,Tirat-Carmel, Israel) in which the ultrasound transducer is housed in the patient table. Alignment between the lesion and the transducer will be obtained in each patient by using a moistened gel pad and degassed water for acoustic coupling. This approach avoided air- skin interfaces, which can cause energy reflection and skin burns. After patient positioning, the lesion is localized with MR for treatment by using variably orientated non enhanced T1- and T2-weighted acquisitions. In general, an ideal 90° incidental angle between the planned focused ultrasound path and the lesion, relative to the bone long axis, is obtained or at least approximated. The shortest skin-lesion distance is selected for the beam pathway. Care will be taken to avoid multiple interfaces (skin, muscle, fasciae) as much as possible so as to minimize deflection of the focused ultrasound beam. Each lesion will be manually segmented by the operator to precisely delineate the nidus, skin surface, and cortical surface of the bone. Sensitive areas surrounding the target volumes will also be drawn to limit the energy and prevent unwanted thermal damage. The treatment plan is than calculated automatically by the ExAblate software according to previously acquired parameters, including the energy (in joules), the interval between two sonications, the sonication duration, and the spot size, which are modifiable by the operator. Thereafter, a low-energy sonication test will be performed to confirm the path and correct direction of the ultrasound beam into the target area and to confirm the planned energy dose and the effective dose deployed to the lesion.
The increase in tissue temperature is evaluated by using real-time MR thermometry of phase-difference fast spoiled gradient-echo sequences (proton resonant frequency shift method). The sequences are acquired to provide temperature-dependent images and real-time mapping of the thermal dose on a preferred imaging plane. The proton resonant frequency shift method starts simultaneously with each sonication. Similar to other treatments of bone lesions that use MR-guided focused ultrasound, the temperature increase is determined on the adjacent periskeletal tissue. In fact, proton resonant frequency sequences cannot effectively measure the temperature on the bone surface because of the absence of moving protons in the cortical zone. Thus, MR thermometry reveals a temperature increase, which propagates by conductive processes from the bone to the immediately adjacent soft tissues that respond linearly to an increase in bone temperature, thereby allowing an accurate measure of heating. Portions of periosteum and adjacent tumor that are not fully ablated can be re-treated if deemed necessary. The critical temperature threshold for ablation is set at 65°C in the soft tissues adjacent to the targeted bone structures. Postprocedural care includes evaluation of possible skin burns, monitoring of vital signs for 2 hours after treatment in the MR department, and administration of analgesic and/or antiemetic drugs if requested. Treatment-related adverse events will be recorded as minor or major on the basis of medical severity, additional treatment, and long-term consequences for patients. Treatment will be performed on an outpatient basis in the patients who receive only local and peripheral anesthesia; the patient who receives general anesthesia is usually hospitalized for 24 hours after treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Alessandro Napoli, MD, PhD
- Phone Number: 3357718114
- Email: alessandro.napoli@uniroma1.it
Study Locations
-
-
-
Rome, Italy, 00100
- Recruiting
- Alessandro Napoli
-
Contact:
- Alessandro Napoli
- Phone Number: +393357718114
- Email: alessandro.napoli@uniroma1.it
-
Principal Investigator:
- Alessandro Napoli, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- clinical and imaging diagnosis of osteoid osteoma
- painful non-vertebral location
Exclusion Criteria:
- general contraindication to MRI
- vertebral location of the lesion
- claustrophobia and prior surgery or RFA are not an absolute exclusion criterion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Osteoid Osteoma
MR guided High Intensity focused ultrasound
|
High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety - Adverse Events (serious and otherwise)
Time Frame: 1 year
|
to assess complications
|
1 year
|
Efficacy (Symptoms reduction)
Time Frame: 4 years
|
Symptoms reduction
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
nidus vascularization (correlation between nidus vascularization reduction and symptoms relieve)
Time Frame: 4 years
|
correlation between nidus vascularization reduction and symptoms relieve
|
4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alessandro napoli, MD, PhD, Sapienza University of Rome, Policlinico Umberto I Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OO-MC-MRGFUS-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoma, Osteoid
-
Children's National Research InstituteCompletedOsteoid OsteomaUnited States
-
Matthew BucknorFocused Ultrasound FoundationRecruitingOsteoid OsteomaUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedOsteoid OsteomaFrance
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Children's National Research InstituteActive, not recruiting
-
University Hospital, Strasbourg, FranceRecruitingPainful Bone Metastases | Superficial Osteoid OsteomaFrance
-
The Hospital for Sick ChildrenSunnybrook Health Sciences CentreCompletedPain | Osteoid Osteoma | Benign Bone TumorCanada
-
Federico II UniversityCompleted
-
Shenzhen Geno-Immune Medical InstituteRecruitingSarcoma | Ewing Sarcoma | Osteoid SarcomaChina
-
Shenzhen Geno-Immune Medical InstituteThe Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children...Recruiting
Clinical Trials on MR guided High Intensity focused ultrasound
-
The Hospital for Sick ChildrenSunnybrook Health Sciences CentreCompletedPain | Osteoid Osteoma | Benign Bone TumorCanada
-
Washington University School of MedicineWithdrawnCervical Cancer | Rectal Cancer | Pelvic Neoplasms | Bladder Cancer | Healthy Participants | Soft-tissue Sarcoma
-
Institute of Cancer Research, United KingdomCancer Research UK; Philips Medical SystemsWithdrawnCancer | Bone MetastasesUnited Kingdom
-
Institute of Cancer Research, United KingdomCompletedCervical Cancer | Ovarian Cancer | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer | Uterine CancerUnited Kingdom
-
Institute of Cancer Research, United KingdomPhilips Medical SystemsCompleted
-
Philips HealthcareCompleted
-
Kyung Won ChangYonsei UniversityActive, not recruitingAlzheimer DiseaseKorea, Republic of
-
Washington University School of MedicineWithdrawn
-
The Hospital for Sick ChildrenSunnybrook Health Sciences CentreRecruitingPain | Bone MetastasesCanada
-
Philips HealthcareCompletedUterine LeiomyomasCanada